Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $456 and keeps an Equal Weight rating on the ...
Discover the latest addition to Children's Hospital Los Angeles' 10 cell and gene therapy treatments, including Casgevy for sickle cell disease ...
The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...
The Motley Fool on MSN13d
2 Magnificent Stocks to Buy That Are Near Their 52-Week LowsCRISPR Therapeutics is a mid-stage biotech specializing in gene editing. The company has just one product on the market, ...
Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...
Look for the launch of Alyftrek to boost Vertex's sales in the coming quarters. Vertex is also picking up momentum with its ...
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood disorders, much of these gains have pared mainly due to the waning ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback